Overview

Brivaracetam (marketed as Briviact) is a next-generation anticonvulsant belonging to the racetam class of compounds, developed as a structural analog of levetiracetam (Keppra) with enhanced pharmacological properties. It was approved by the U.S. Food and Drug Administration in 2016 and by the European Medicines Agency for the adjunctive treatment of focal (partial-onset) seizures in adults and adolescents aged 16 years and older, with subsequent approvals extending to younger pediatric populations. Brivaracetam is available in oral tablet, oral solution, and intravenous formulations.

The primary mechanism of action of brivaracetam involves high-affinity binding to synaptic vesicle glycoprotein 2A (SV2A), a transmembrane protein ubiquitously expressed in synaptic vesicles that modulates neurotransmitter release. Brivaracetam demonstrates approximately 15–30 times greater binding affinity for SV2A compared to levetiracetam, and it exhibits faster brain penetration and more selective engagement of its target. Unlike levetiracetam, which has additional effects on ion channels and other receptors, brivaracetam appears to act more specifically through SV2A modulation, which may contribute to its distinct tolerability profile.

In pivotal phase III clinical trials, brivaracetam demonstrated statistically significant reductions in focal seizure frequency compared to placebo when used as adjunctive therapy. The most common adverse effects include somnolence, dizziness, and fatigue, but notably, the incidence of behavioral and psychiatric adverse events (such as irritability and aggression) appears to be lower than that observed with levetiracetam, making it a potential alternative for patients who experience neuropsychiatric side effects with the older compound. Brivaracetam is metabolized primarily by CYP2C19 and amidase hydrolysis, and dosage adjustments may be warranted in patients with hepatic impairment.

Mechanism of Action

High-Affinity SV2A Ligand

Brivaracetam is a next-generation synaptic vesicle glycoprotein 2A (SV2A) ligand and chemical analog of levetiracetam, with approximately 15-30-fold higher binding affinity for SV2A (IC50 ~ 28 nM vs. ~770 nM for levetiracetam). SV2A is a 12-transmembrane domain glycoprotein ubiquitously expressed on synaptic vesicles throughout the CNS, functioning as a critical regulator of vesicle-mediated neurotransmitter release (PMID: 26332317).

SV2A-Mediated Vesicle Release Modulation

SV2A modulates neurotransmitter release by interacting with synaptotagmin-1, the primary calcium sensor for fast synchronous exocytosis. SV2A assists in the proper priming of synaptic vesicles by facilitating the conformational change of synaptotagmin-1 required for calcium-dependent SNARE complex assembly. Brivaracetam binding to SV2A alters this interaction, reducing the readily releasable pool of synaptic vesicles and attenuating excessive neurotransmitter release during high-frequency neuronal firing characteristic of epileptic seizures, without significantly affecting normal synaptic transmission (PMID: 22538469).

Differential Mechanism from Levetiracetam

Unlike levetiracetam, brivaracetam has negligible activity at AMPA receptors, GABA_A receptors, or neuronal voltage-gated sodium channels at therapeutic concentrations. Its anticonvulsant effect is attributed almost exclusively to SV2A binding. Brivaracetam also demonstrates a faster brain penetration rate due to higher lipophilicity (LogP ~ 1.04), achieving maximal brain occupancy within minutes of administration compared to hours for levetiracetam (PMID: 24519919).

Network Excitability & Epileptogenesis

Chronic SV2A modulation by brivaracetam may have anti-epileptogenic properties beyond acute seizure suppression. In kindling models, brivaracetam slows the rate of seizure progression and reduces interictal spike frequency, potentially by restoring SV2A protein levels that decline during epileptogenesis and by normalizing aberrant synaptic vesicle cycling in reorganized hippocampal circuits (PMID: 25307356).

Research

Safety Profile

Safety Profile: Brivaracetam

Common Side Effects

• Somnolence/drowsiness (~15-20% of patients)
• Dizziness (~11-16%)
• Fatigue (~9-14%)
• Nausea and vomiting (~5-9%)
• Headache
• Irritability and mood changes
• Upper respiratory tract infections
• Decreased appetite

Serious Adverse Effects

• Suicidal ideation and behavior: Class warning for all antiepileptic drugs; monitor for depression, anxiety, behavioral changes
• Psychiatric symptoms: Psychotic symptoms, aggression, agitation, anger reported (lower incidence than levetiracetam)
• Hypersensitivity reactions: Bronchospasm, angioedema (rare)
• Hematologic: Leukopenia, neutropenia (rare; periodic CBC recommended)
• Hepatic: Elevated transaminases; rare cases of jaundice
• Withdrawal seizures: Abrupt discontinuation may precipitate seizures or status epilepticus; taper gradually

Contraindications

• Known hypersensitivity to brivaracetam, other pyrrolidone derivatives, or any excipients
• Severe hepatic impairment (Child-Pugh C) -- maximum recommended dose is 150 mg/day with dose adjustment

Drug Interactions

• Rifampin: Strong enzyme inducer decreases brivaracetam plasma levels by ~45%; dose adjustment needed
• Carbamazepine: Brivaracetam increases carbamazepine-epoxide (active metabolite) levels by ~25%; monitor for carbamazepine toxicity
• Phenytoin: Brivaracetam may increase phenytoin levels by inhibiting CYP2C19; monitor phenytoin levels
• Levetiracetam: No additional benefit from co-administration (same SV2A target); not recommended together
• Oral contraceptives: No clinically significant interaction at recommended doses
• Alcohol/CNS depressants: Additive sedation; avoid or use with caution

Population-Specific Considerations

• Pregnancy: Category C equivalent; crosses placenta. Registry data limited. Folic acid supplementation recommended. Enroll in pregnancy registries
• Lactation: Excreted in breast milk; weigh benefits vs. risks. Monitor infant for sedation
• Pediatric (4+ years): FDA-approved for adjunctive treatment of partial-onset seizures; weight-based dosing
• Elderly: No specific dose adjustment; however, increased sensitivity to CNS effects
• Hepatic impairment: Reduce starting dose in all stages; max 150 mg/day in severe impairment (Child-Pugh C)
• Renal impairment: No dose adjustment needed, including in dialysis patients
• Psychiatric history: Use with heightened monitoring; lower risk of behavioral AEs than levetiracetam but not negligible

Pharmacokinetic Profile